Literature DB >> 11544315

Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes.

P Sliz1, O Michielin, J C Cerottini, I Luescher, P Romero, M Karplus, D C Wiley.   

Abstract

We have determined high-resolution crystal structures of the complexes of HLA-A2 molecules with two modified immunodominant peptides from the melanoma tumor-associated protein Melan-A/Melanoma Ag recognized by T cells-1. The two peptides, a decamer and nonamer with overlapping sequences (ELAGIGILTV and ALGIGILTV), are modified in the second residue to increase their affinity for HLA-A2. The modified decamer is more immunogenic than the natural peptide and a candidate for peptide-based melanoma immunotherapy. The crystal structures at 1.8 and 2.15 A resolution define the differences in binding modes of the modified peptides, including different clusters of water molecules that appear to stabilize the peptide-HLA interaction. The structures suggest both how the wild-type peptides would bind and how three categories of cytotoxic T lymphocytes with differing fine specificity might recognize the two peptides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544315     DOI: 10.4049/jimmunol.167.6.3276

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design.

Authors:  Francis K Insaidoo; Oleg Y Borbulevych; Moushumi Hossain; Sujatha M Santhanagopolan; Tiffany K Baxter; Brian M Baker
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

3.  Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules.

Authors:  Sergio Madurga; Ignasi Belda; Xavier Llorà; Ernest Giralt
Journal:  Protein Sci       Date:  2005-08       Impact factor: 6.725

4.  Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition.

Authors:  William F Hawse; Brian E Gloor; Cory M Ayres; Kevin Kho; Elizabeth Nuter; Brian M Baker
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

5.  Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.

Authors:  Oleg Y Borbulevych; Tiffany K Baxter; Zhiya Yu; Nicholas P Restifo; Brian M Baker
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

6.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

7.  Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35.

Authors:  Marion Tarbe; John J Miles; Emily S J Edwards; Kim M Miles; Andrew K Sewell; Brian M Baker; Stéphane Quideau
Journal:  ChemMedChem       Date:  2020-04-06       Impact factor: 3.466

8.  Two distinct conformations of a rinderpest virus epitope presented by bovine major histocompatibility complex class I N*01801: a host strategy to present featured peptides.

Authors:  Xin Li; Jun Liu; Jianxun Qi; Feng Gao; Qirun Li; Xiaoying Li; Nianzhi Zhang; Chun Xia; George F Gao
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

9.  Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.

Authors:  Rieuwert Hoppes; Rimke Oostvogels; Jolien J Luimstra; Kim Wals; Mireille Toebes; Laura Bies; Reggy Ekkebus; Pramila Rijal; Patrick H N Celie; Julie H Huang; Maarten E Emmelot; Robbert M Spaapen; Henk Lokhorst; Ton N M Schumacher; Tuna Mutis; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2014-10-13       Impact factor: 5.422

10.  Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Authors:  Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Journal:  J Mol Biol       Date:  2007-07-26       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.